# FibroGen, Inc.

> FibroGen, Inc. is a San Francisco biopharmaceutical company that spent three decades building first-in-class medicines around hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology. Its best-known drug, roxadustat, is an oral treatment for anemia approved in China, Japan and Europe. After selling its China business to AstraZeneca in 2025 and paying down debt, the company rebranded as Kyntra Bio (Nasdaq: KYNB) in January 2026 to concentrate on oncology and rare disease, led by FG-3246, a first-in-class CD46-targeting antibody-drug conjugate for metastatic prostate cancer.

- **Founded:** 1993
- **Headquarters:** San Francisco, California, United States
- **Founders:** Thomas B. Neff (Founder & longtime CEO (1993-2019)), Kari Kivirikko (Scientific co-founder (collagen/prolyl hydroxylase biology))
- **Team size:** Reported at roughly 280 employees historically; substantially smaller after the 2025 China divestiture (Wikipedia cites ~34 US employees as of Dec 2025)
- **Products:** FG-3246 (FOR46), FG-3180, Roxadustat (Evrenzo), FG-3165, Pamrevlumab
- **Notable:** Roxadustat approved for anemia of chronic kidney disease in China (2018), Japan (2019), Europe (2021) and other markets, Completed the largest US biotech IPO in 12 years (2014), raising ~$172M net, Sold FibroGen China to AstraZeneca for ~$220M in 2025, paying off its term loan and extending cash runway into 2028

## Products & services

- **FG-3246 (FOR46)** — First-in-class CD46-targeting antibody-drug conjugate (in-licensed from Fortis Therapeutics); lead asset in a Phase 2 monotherapy trial for metastatic castration-resistant prostate cancer (mCRPC).
- **FG-3180** — CD46-targeted PET imaging biomarker/companion diagnostic designed to pair with FG-3246 in prostate cancer.
- **Roxadustat (Evrenzo)** — Oral HIF-prolyl hydroxylase inhibitor for anemia of chronic kidney disease; approved in China, Japan, Europe and other markets. Repositioned as a Phase 3-ready asset for anemia in lower-risk myelodysplastic syndromes with FDA Orphan Drug Designation.
- **FG-3165** — Galectin-9 (Gal9)-targeting monoclonal antibody for solid tumors; FDA cleared the IND in June 2024, Phase 1 planned.
- **Pamrevlumab** — Anti-CTGF human monoclonal antibody once developed for idiopathic pulmonary fibrosis, Duchenne muscular dystrophy and pancreatic cancer; discontinued after Phase 3 failures in 2023-2024.

## Achievements

- Roxadustat approved for anemia of chronic kidney disease in China (2018), Japan (2019), Europe (2021) and other markets
- Completed the largest US biotech IPO in 12 years (2014), raising ~$172M net
- Sold FibroGen China to AstraZeneca for ~$220M in 2025, paying off its term loan and extending cash runway into 2028
- Advanced FG-3246 into a Phase 2 monotherapy trial for metastatic castration-resistant prostate cancer (2025)
- Secured FDA Orphan Drug Designation for roxadustat in myelodysplastic syndromes

## Latest updates

- **2026-01** — FibroGen rebranded as Kyntra Bio; common stock began trading on Nasdaq under the ticker KYNB on Jan 8, 2026, reflecting a sharpened focus on oncology and rare disease.
- **2025-09** — Initiated a Phase 2 monotherapy dose-optimization trial of FG-3246 in metastatic castration-resistant prostate cancer; interim analysis expected in 2H 2026.
- **2025-08** — Completed the sale of FibroGen China to AstraZeneca for approximately $220 million, repaying its term loan and extending cash runway into 2028.
- **2024-06** — FDA cleared the IND for FG-3165, a galectin-9-targeting monoclonal antibody for solid tumors.
- **2024-02** — Regained all rights to roxadustat from AstraZeneca in the US and other territories, except China and South Korea.

## Links

- Website: https://www.kyntrabio.com
- LinkedIn: https://www.linkedin.com/company/kyntrabio
- Twitter/X: https://twitter.com/FibroGenInc

---

Profile page: https://yespress.io/fibrogen-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-15